FDA Approves Leqembi, a New Alzheimer’s Drug

The FDA approved the new Alzheimer’s drug lecanemab (BAN2401), which will be sold under the brand name Leqembi developed by Eisai and Biogen last week for patients with mild cognitive impairment or early Alzheimer’s dementia. Leqembi was approved under the FDA’s accelerated review process, an expedited pathway that speeds access to a drug based on …

FDA Approves Leqembi, a New Alzheimer’s Drug Read More »